🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

We are profoundly grateful that Dr. Ruth Gottesman, Professor Emerita of Pediatrics at Albert Einstein College of Medicine - Official, has made a transformational gift to #MontefioreEinstein—the largest to any medical school in the country—that ensures no student has to pay tuition again. bit.ly/3wvBj7y

Congratulations to the incoming PGY-1 class! Very excited to welcome our new residents! #PathMatch24

An interesting case I treated a year ago, I am glad this new medication helps her. A case report of pegcetacoplan use for a pregnant woman with paroxysmal nocturnal hemoglobinuria - Research and Practice in Thrombosis and Haemostasis rpthjournal.org/article/S2475-…

Updated National Comprehensive Cancer Network (NCCN) guidelines (1.2025) are in, with some major changes for systemic therapies: 1) Ipi+Nivo is now a preferred regimen in fav-risk ccRCC 2) Len+Pem/Cabo+Nivo are now preferred regimens for non-clear cell RCC 3) Adjuvant Pembro is now Category 1 KidneyCAN

Congratulations Neha! Neha Vapiwala

Like this review. Specially, the figures are beautiful.

Just in Annals of Oncology 👉on the heels of the recent approval of belzutifan in mRCC #kidneycancer , herein we show in a ph2 randomized trial👉more belzutifan (200 mg vs 120 mg QD) was not better👇Link: tinyurl.com/nrsxp8s4 UroToday.com OncoAlert KidneyCAN Huntsman Cancer Institute

How does Sunniforcast data fit into the non-clear cell landscape? Figure below may help (with shortcomings)?? Larger circles =⬆️ numbers, ringed circles = papillary only subsets. Are VEGF/PD1 doublets the standard of care. Nashville #UromigosLive live session this Saturday 28th!

Excellent review

Nice summary.

Meta-Analysis of Age, Sex, and Race Disparities in the Era of Contemporary Urothelial Carcinoma Treatment mdpi.com/2977898 #mdpicancers via Cancers MDPI

Thanks for our resident Adam Barsouk MD hard work and dedication. Appreciate Ronac Mamtani support for your review article. We have found women's bladder cancer still has inferior outcomes even in the modern treatment era.

Legendary

From @asco JCO Oncology Practice 71% of US counties either lack an oncologist (20%) or lack an open cancer trials (50%). Meanwhile trends show declining % of oncologists in rural communities. Pair this with @wsj piece on community oncs being overwhelmed by clinical advances.

Just in CA: A Cancer Journal for Clinicians 👉Comprehensive review of efficacy & safety data of PARP inhibitors across cancer types #prostatecancer, #ovariancancer, #breastcancer & others 👉Open access weblink👉 bit.ly/42apBgy @chadihc98 GU Cancer Research Program @HuntsmanCancer  OncoAlert UroToday.com PCF Science

Specially interested to see 1 and 2.

A Penn Medicine pilot study led by Ronac Mamtani, MD (Ronac Mamtani), demonstrated that text message check-ins, instead of in-person visits, could save cancer patients more than 60 minutes per appointment. HemOnc Today spr.ly/60122Rwj0

One of my patient was in this trial. Amazing work from Penn. Penn Medicine - Abramson Cancer Center Enhanced CAR T-Cell Therapy for Lymphoma after Previous Failure | New England Journal of Medicine nejm.org/doi/full/10.10…

Congratulations Vivek! Ronac Mamtani Penn Medicine - Abramson Cancer Center

Terrific presentation by #VivekNarayan Ab#4507 ASCO #ASCO25 👉5-yr f/u of Ph2 LITESPARK-004👉Belzutifan shows durable activity and manageable toxicity in VHL-associated neoplasms (ORR 70% in RCC) #kidneycancer👇OncoAlert UroToday.com @kidneycancer